Sunitinib, a PDGFR and VEGFR inhibitor, was approved in the treatment of renal cell carcinoma and gastrointestinal stromal tumor, whereas osimertinib, an EGFR inhibitor, was approved in the treatment of NSCLC [38,39,40]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.